The Board appointed Fred Hassan as Chair effective October 31, 2026. The company reported a net loss of $119.0 million for Q3 2026, with revenue rising to $18.6 million driven by a $10.0 million Sanofi milestone. Pro forma cash is approximately $748.7 million following an October offering, extending the runway into 2029. Recursion Pharmaceuticals operates in the biotechnology sector, pioneering AI-enabled drug discovery and development.
